CU06-1004 effectively inhibited the progression toward chronic intestinal inflammation and subsequent colitis-associated colorectal cancer by suppressing immune cell infiltration, reducing pro-inflammatory cytokine production, limiting tumor cell proliferation, and downregulating oncogenic proteins such as β-catenin and c-Myc. Here, MYC is linked to colitis.